BIOMAT Database Logo BIOMAT Database Logo

Novel N-Heteroaryl Indazole Derivatives as LRRK2 Inhibitors for Treating Parkinson's Disease. 2021

Ram W Sabnis
Smith, Gambrell & Russell LLP, 1230 Peachtree Street NE, Suite 3100, Atlanta, Georgia 30309, United States.

UI MeSH Term Description Entries

Related Publications

Ram W Sabnis
New Pyrrolopyrimidines as LRRK2 Inhibitors for Treating Parkinson's Disease.
August 2023, Current medicinal chemistry,
Ram W Sabnis
Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease.
December 2022, Journal of medicinal chemistry,
Ram W Sabnis
Inhibitors of LRRK2 as Treatment for Parkinson's Disease: Patent Highlight.
September 2012, ACS medicinal chemistry letters,
Ram W Sabnis
Novel dihydrothieno[2,3-e]indazole derivatives as IκB kinase inhibitors.
March 2011, Bioorganic & medicinal chemistry letters,
Ram W Sabnis
Discovery of Novel Indazole Chemotypes as Isoform-Selective JNK3 Inhibitors for the Treatment of Parkinson's Disease.
January 2023, Journal of medicinal chemistry,
Ram W Sabnis
Investigating novel thiazolyl-indazole derivatives as scaffolds for SARS-CoV-2 MPro inhibitors.
April 2022, European journal of medicinal chemistry reports,
Ram W Sabnis
Heterocyclic indazole derivatives as SGK1 inhibitors, WO2008138448.
January 2010, Expert opinion on therapeutic patents,
Ram W Sabnis
N-Aromatic-Substituted Indazole Derivatives as Brain-Penetrant and Orally Bioavailable JNK3 Inhibitors.
October 2021, ACS medicinal chemistry letters,
Ram W Sabnis
QSAR Modelling to Identify LRRK2 Inhibitors for Parkinson's Disease.
February 2019, Journal of integrative bioinformatics,
Ram W Sabnis
A step forward for LRRK2 inhibitors in Parkinson's disease.
June 2022, Science translational medicine,
Copied contents to your clipboard!